<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357887</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2016/ET-01</org_study_id>
    <nct_id>NCT03357887</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome</brief_title>
  <acronym>T-RIS</acronym>
  <official_title>Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To look at the prognostic value of new biomarkers in CSF and serum for characterisation of
      multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of tumour necrosis factor receptor in cerebrospinal fluid</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of protein X in cerebrospinal fluid</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of protein Y in cerebrospinal fluid</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of secreted glycoprotein in cerebrospinal fluid</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of tumour necrosis factor receptor in serum</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of protein X in serum</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of protein Y in serum</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of secreted glycoprotein in serum</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Log-rank test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis).</measure>
    <time_frame>Baseline</time_frame>
    <description>Multivariate analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Radiologically Isolated Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of cerebrospinal fluid and serum</intervention_name>
    <description>Analysis of biomarkers in patient biological samples</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from whom prospective samples have been collected and conserved in the biobank at
        Nice as part of the RISC (Radiologically Isolated Syndrome Consortium).

        100 patients with Radiologically Isolated Syndrome as diagnosed by MRI using the Okuda 2009
        criteria (65 RIS-: not converted after at least 2 years of follow-up; 35 RIS+).

        30 patients with recurrent-remittent multiple sclerosis 30 symptomatic control patients 20
        control patients with inflammatory disease 20 control patients with non-inflammatory
        neurological disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients have given their free consent for use of their samples in research

          -  Patients have at least 2 years of clinical and radiological follow-up data available
             Exclusion criterion

          -  No follow-up of patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Thouvenot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Thouvenot</last_name>
    <phone>+33 (0)4 66 68 32 61</phone>
    <email>eric.thouvenot@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

